electroCore Inc

Financials

Mittelzufluss aus laufender Geschäftstätigkeit -1.25 M-4.36 M-623 K-1.67 M-1.54 M -8.19 M Mittelzufluss aus Investitionstätigkeit -501 K4.5 M185 K-1.33 M518 K 3.88 M Zahlungsströme aus der Finanzierungstätigkeit 371 K180 K3 0007.48 M-40 K 7.63 M Freier Cashflow -1.25 M-4.39 M-648 K-1.67 M-1.54 M -8.25 M

electroCore, Inc. is a medical technology company based in Basking Ridge, New Jersey. electroCore was co-founded in 2005 by JP Errico, Thomas J. Errico, MD, Charles Theofilos, MD, and Peter Staats, MD. The current chief executive officer is Daniel S. Goldberger. electroCore has one product called gammaCore, a non-invasive, commercially available product that uses vagus nerve stimulation.

ECOR

Financials

electroCore Inc

Nachrichten

electroCore (ECOR) Moves 7.1% Higher: Will This Strength Last?

electroCore: H.C. Wainwright bestätigt Kaufempfehlung und Kursziel von 18 US-Dollar

electroCore, Inc. (ECOR) Q4 2025 Earnings Call Transcript

electroCore, Inc. (ECOR) Reports Q4 Loss, Lags Revenue Estimates

Earnings Call Transkript: Electrocore meldet starkes Umsatzwachstum für Q4 2025

electroCore meldet 27 % Umsatzwachstum, CEO kündigt Rücktritt an

MARKER THERAPEUTICS, INC. (MRKR) Reports Q4 Loss, Tops Revenue Estimates

Analysts Estimate Nektar Therapeutics (NKTR) to Report a Decline in Earnings: What to Look Out for

OmniAb, Inc. (OABI) Reports Q4 Loss, Misses Revenue Estimates

electroCore, Inc. (ECOR) May Report Negative Earnings: Know the Trend Ahead of Q4 Release

Amneal Pharmaceuticals (AMRX) Q4 Earnings Top Estimates

H.C. Wainwright senkt Kursziel für electroCore wegen höherer Kosten auf 18 US-Dollar